• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Crizanlizumab use lowers rates of sickle cell crises

byDayton McMillanandShaidah Deghan, MSc. MD
February 2, 2017
in Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients with sickle cell disease treated with high-dose crizanlizumab experienced lower annualized rates of sickle cell crisis compared to placebo treatment, regardless of their baseline use of hydroxyurea.

2. Those treated with high-dose crizanlizumab remained without a sickle cell crisis on average significantly longer into the study period than those treated with placebo.

Evidence Rating: 1 (Excellent)

Study Rundown: The pathogenesis of sickle cell disease has been reported to be based on vaso-occlusive events which increases tissue inflammation. In addition to damaging tissue, these occlusive events are reported to be extremely painful and contribute to increased mortality risk amongst those with sickle cell disease. Adherence of erythrocytes and leukocytes to vascular endothelium is a fundamental aspect of vaso-occlusive events, and P-selectin expression by endothelium has been shown to promote adherence. This study aimed to evaluate the effects of crizanlizumab, an antibody against P-selectin, on reducing the rate of a sickle cell crisis.

People with sickle cell disease, including those on baseline hydroxyurea or not, who had experienced recent sickle cell-related pain crisis were included in the trial. Patients were randomized on a 1:1:1 fashion into groups receiving high-dose crizanlizumab, low-dose crizanlizumab, or a placebo. Treatments were administered for 52 weeks, and patients were followed to assess for occurrence of sickle cell-related pain crisis, time from study initiation to sickle cell-related pain crisis, and other markers of treatment efficacy and safety. Those treated with high-dose crizanlizumab experienced significantly fewer pain crises per year than those in the placebo group. A first sickle cell-related pain crisis during the study period occurred later on average for those in the high-dose crizanlizumab group compared to placebo.

Click to read the study, published today in NEJM

RELATED REPORTS

#VisualAbstract: Dihydroartemisinin–Piperaquine is More Effective Than Sulfadoxine–Pyrimethamine for Malaria Chemoprevention

#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia

#VisualAbstract: Moderate-dose hydroxyurea does not decrease stroke incidence but may lower hospitalization rates in children with sickle cell anaemia, compared to low-dose hydroxyurea

Relevant Reading: Inhibition of cell adhesion by anti–P-selectin aptamer: a new potential therapeutic agent for sickle cell disease

In-Depth [randomized controlled trial]: From 2013 to 2015, 198 patients at 60 international sites were randomly assigned to receive high-dose crizanlizumab (n = 67), low-dose crizanlizumab (n = 66), or placebo (n = 65). Patients included in the study had sickle cell disease, were 16-65 years old, had 2-10 sickle crises in the past year, and could be on hydroxyurea or not. Those being chronically transfused were not included. Randomization to treatment group was stratified by number of crises in the prior year (2-4 or 5-10) and hydroxyurea use (yes or no). The study included a 4 week loading phase, 52-week treatment phase with treatment administered every 4 weeks, and an evaluation phase 6 weeks after conclusion of treatments. Assessed via intention-to-treat, those in the high-dose group experienced 45.3% fewer crises per year than those in the placebo group (rate of crisis 1.63 vs. 2.98, p = 0.01). A per-protocol analysis of participants in the high-dose group demonstrated a 52.3% fewer crises per year than the placebo group (rate of crisis 1.04 vs. 2.18, p = 0.02). The low-dose group was not significantly different from the placebo group in either of the prior analyses. Patients treated with or without hydroxyurea experienced fewer crisis per year in the high-dose group compared to the low dose group, though the difference was not statistically significant (rate of crisis with hydroxyurea 2.43 vs. 3.58; rate of crisis without hydroxyurea 1.00 vs. 2.00). The median time to first crisis after starting treatment was longer in the high-dose group compared to those treated with placebo (rate of crisis 4.07 vs 1.38 months, p = 0.001). Serious adverse events such as headache, back pain, nausea, arthralgia were reported in 55 participants and was not significantly higher in one study group over the others. No detectable antibody response against crizanlizumab was detected in any patient during the trial.

Image: CC/Wiki

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: sickle cell anemia
Previous Post

2 Minute Medicine Rewind January 30, 2017

Next Post

Adding antiandrogen therapy to radiation improves overall survival in recurrent prostate cancer

RelatedReports

#VisualAbstract: Dihydroartemisinin–Piperaquine is More Effective Than Sulfadoxine–Pyrimethamine for Malaria Chemoprevention
StudyGraphics

#VisualAbstract: Dihydroartemisinin–Piperaquine is More Effective Than Sulfadoxine–Pyrimethamine for Malaria Chemoprevention

January 10, 2025
#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia
StudyGraphics

#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia

May 4, 2022
#VisualAbstract: Moderate-dose hydroxyurea does not decrease stroke incidence but may lower hospitalization rates in children with sickle cell anaemia, compared to low-dose hydroxyurea
StudyGraphics

#VisualAbstract: Moderate-dose hydroxyurea does not decrease stroke incidence but may lower hospitalization rates in children with sickle cell anaemia, compared to low-dose hydroxyurea

January 13, 2022
#VisualAbstract ESCORT-HU highlights the real-life positive benefit-to-risk ratio of hydroxyurea in patients with sickle cell disease
StudyGraphics

#VisualAbstract ESCORT-HU highlights the real-life positive benefit-to-risk ratio of hydroxyurea in patients with sickle cell disease

October 8, 2021
Next Post
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

Adding antiandrogen therapy to radiation improves overall survival in recurrent prostate cancer

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors

Centrifugal-flow devices noninferior to axial-flow in advanced heart failure: The ENDURANCE trial

Laser therapy may be effective in patients with infantile hemangiomas

Laser therapy may be effective in patients with infantile hemangiomas

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind June 16, 2025
  • Transcatheter closure of patent ductus arteriosus demonstrates similar outcomes compared to surgical repair
  • #VisualAbstract: Encorafenib, Cetuximab, and mFOLFOX6 Improves Survival in BRAF-Mutated Colorectal Cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.